Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
March 26, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
March 11, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy...
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
March 05, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
February 22, 2024 07:32 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
February 22, 2024 07:31 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
February 22, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay...
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
February 15, 2024 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
February 13, 2024 07:37 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
January 25, 2024 08:00 ET
|
Ocular Therapeutix, Inc.
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE...
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 18, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...